Patents by Inventor Steve Swann

Steve Swann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES
    Publication number: 20230158010
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4, R5, R6, X1, X2, X3 and X4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT4 receptor.
    Type: Application
    Filed: May 3, 2021
    Publication date: May 25, 2023
    Inventors: Tony S. GIBSON, Steve SWANN
  • 3-AMINO-4H-BENZO[E][1,2,4]THIADIAZINE 1,1-DIOXIDE DERIVATIVES AS INHIBITORS OF MRGX2
    Publication number: 20220119361
    Abstract: Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R1, R2, R3, R4 and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.
    Type: Application
    Filed: April 28, 2020
    Publication date: April 21, 2022
    Inventors: Simone BIGI, Alison L. CHAMBERS, Tony GIBSON, Jason PICKENS, Steve SWANN, Angie VASSAR, Feng ZHOU, Mitsunori KONO, Masaki SETO, Zenyu SHIOKAWA
  • Heterocyclic compound
    Patent number: 11236099
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: February 1, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017530
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • HETEROCYCLIC COMPOUND
    Publication number: 20210139491
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: June 19, 2018
    Publication date: May 13, 2021
    Inventors: Kazuaki TAKAMI, Masaki SETO, Shinobu SASAKI, Haruhi ANDO, Masaki OGINO, Tomoko OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Yasuhiro TSUKIMI, Masami YAMADA, Kenichiro SHIMOKAWA, Takeshi WAKABAYASHI, Masataka MURAKAMI, Makoto FUSHIMI, Tomohiro OKAWA, Jinichi YONEMORI, Tomohiro OHASHI, Hideo SUZUKI, Hironobu MAEZAKI, Ayumu SATO, Yasutomi ASANO, Steve SWANN
  • Heteroarylamide inhibitors of TBK1
    Patent number: 9994547
    Abstract: Disclosed are compounds of formula 1: which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 12, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Simone Bigi, Walter Keung, Steve Swann, Phong H. Vu, Steven John Woodhead, Anthony R. Gangloff
  • HETEROARYLAMIDE INHIBITORS OF TBK1
    Publication number: 20170313675
    Abstract: Disclosed are compounds of formula 1: which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: October 2, 2015
    Publication date: November 2, 2017
    Inventors: Simone Bigi, Walter Keung, Steve Swann, Phong H. Vu, Steven John Woodhead, Anthony R. Gangloff
  • 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
    Patent number: 8445686
    Abstract: The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs).
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: May 21, 2013
    Assignee: AbbVie Inc.
    Inventors: Helmut Mack, Nicole Teusch, Bernhard K. Mueller, Wilfried Hornberger, Michael F. Jarvis, Daryl Sauer, Steve Swann, Jr., Dominique Bonafoux, Ryan Keddy, Adrian Donald Hobson, Anil Vasudevan
  • 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS
    Publication number: 20100273828
    Abstract: The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs).
    Type: Application
    Filed: August 26, 2008
    Publication date: October 28, 2010
    Inventors: Helmut Mack, Nicole Teusch, Bernhard K. Müller, Wilfried Hornberger, Michael F. Jarvis, Daryl Sauer, Steve Swann, JR., Anil Vasudevan